3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
5
Gynecologic
2
Gastrointestinal
2
Head & Neck
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
17
Head and Neck Neoplasms
14
Nasopharyngeal Carcinoma
8
Carcinoma, Non-Small-Cell Lung
5
Thyroid Neoplasms
4
Stomach Neoplasms
4
Salivary Gland Neoplasms
4
Neoplasms
4
Nasopharyngeal Neoplasms
4
Esophageal Neoplasms
4
Radiation Injuries
3
Neoplasm Metastasis
3
Melanoma
3
Esthesioneuroblastoma, Olfactory
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Tongue Neoplasms
2
Thyroid Carcinoma, Anaplastic
2
Pharyngeal Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Mouth Neoplasms
2
Lymphoid Interstitial Pneumonia
2
Endometrial Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Squamous Cell
2
Carcinoma, Renal Cell
2
Carcinoma, Merkel Cell
2
Carcinoma
2
Interventions
pembrolizumab
13
Nivolumab
6
Docetaxel
6
cemiplimab
5
avelumab
5
atezolizumab
5
Trastuzumab
5
Carboplatin
4
durvalumab
3
Polymerase Chain Reaction
3
Magnetic Resonance Spectroscopy
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Cisplatin
3
Biopsy
3
zimberelimab
2
utomilumab
2
ulixertinib
2
tisotumab vedotin
2
pertuzumab
2
palbociclib
2
belinostat
2
amminedichloro(2-methylpyridine)platinum(II)
2
Tetrahydrouridine
2
Radiotherapy
2
Radiosurgery
2
Oxaliplatin
2
Nicotine
2
Ipilimumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urinary Bladder Neoplasms
×
Bevacizumab
×
Head & Neck
×
Clear all
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled